{
  "main_header": {
    "sid": 650679,
    "name": "Vivo Bio Tech",
    "stock_name": "Vivo Bio Tech",
    "full_name": "Vivo Bio Tech Ltd.",
    "name_url": "stocks-analysis/vivo-bio-tech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "34.55",
    "chg": -0.34,
    "chgp": "-0.97%",
    "dir": -1,
    "prev_price": "34.89",
    "mcapval": "59.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 511509,
    "symbol": null,
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE380K01017",
    "curr_date": "Apr 11, 12:50 PM",
    "curr_time": "00:16 AM",
    "bse_nse_vol": "2.89 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivo-bio-tech-650679-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vivo Bio Tech Faces Revenue Growth Challenges Amid Positive Short-Term Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivo-bio-tech-downgraded-to-sell-amid-concerns-over-financial-performance-and-debt-service-1423436",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/VivoBioTech_mojoScore_682519.png",
        "date": "2025-03-18 08:06:24",
        "description": "Vivo Bio Tech, a microcap in the Pharmaceuticals & Drugs sector, has experienced a recent evaluation adjustment. The company reported positive quarterly profits but faces long-term challenges, including declining net sales growth and scrutiny over debt management. Additionally, promoter holding has decreased, indicating potential shifts in stakeholder confidence."
      }
    ],
    "total": 17,
    "sid": "650679",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/vivo-bio-tech-650679"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "08-Apr-2025",
      "details": "The company has allotted 311111 equity shares of Rs. 10/- each at an issue price of Rs. 45/- (premium of Rs. 35/- on each equity share) on conversion of warrants issued on preferential basis.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Allotment",
      "datetime": "29-Mar-2025",
      "details": "Company has allotted 296296 equity shares of Rs. 10/- each at an issue price of Rs.45/- (premium of Rs.35/- on each equity share) on conversion of warrants issued on preferential basis.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Mar-2025",
      "details": "Closure of Trading Window",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vivo Bio Tech Faces Revenue Growth Challenges Amid Positive Short-Term Financials

2025-03-18 08:06:24

Vivo Bio Tech, a microcap in the Pharmaceuticals & Drugs sector, has experienced a recent evaluation adjustment. The company reported positive quarterly profits but faces long-term challenges, including declining net sales growth and scrutiny over debt management. Additionally, promoter holding has decreased, indicating potential shifts in stakeholder confidence.

Read More

View All News